PGx Testing Effectively Addresses Trial and Error Rx Prescribing: RDx BioScience Points to Lower Risk of Adverse Drug Events, Reduced Costs, Improved Outcomes

KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/pharmacogenomics?src=hash” target=”_blank”gt;#pharmacogenomicslt;/agt;–With adverse drug events (ADEs) triggering an estimated 700,000
ED visits and 120,000 hospitalizations, RDx
BioScience (RDx)
points to the benefits of pharmacogenomics (PGx)
testing to effectively address trial-and-error medicine, improve patient
outcomes and impact the $3.5 billion in extra medical costs resulting
from ADEs. RDx, a single source for care quality, risk evaluation and
opioid expertise powered by a fast, full-service laboratory that
includes PGx testing, categorizes ADEs as a serious public health issue
that doubles the cost for treatment, lengths of stay, and patient
mortality – with the number of ADEs reported to the FDA rising
dramatically.

“The essence of PGx is this: giving the right dose of the right drug,
for the right indication, for the right patient at the right time,” says
Scott Howell, D.O., MPH &TM, CPE, chief medical officer, RDx. “The use
of PGx in clinical practice is evolving as new discoveries make it
possible and cost-effective to identify a patient’s unique genetic
makeup and apply this information to treating medical conditions.”

PGx testing reveals a patients’ risks of serious side effects and
reduced drug effectiveness, enabling physicians to make clinical
decisions about prescribing that improve therapeutic outcomes. PGx
testing can analyze the genetic makeup of individuals and determine how
they metabolize nearly 95 percent of the most commonly prescribed oral
medications.

“PGx testing is becoming the standard of care nationwide because it
ensures that plan members are on the correct medication and dosage –
right from the beginning,” says Dr. Howell. “This is especially
important for employers, with research showing that with the right
medication
and dosage, employee symptoms are better treated,
speeding their return to work and enabling greater productivity.

The U.S. Department of Health and Human Services says PGx testing for
potential ADEs or ineffective drug responses may reduce
healthcare costs
over the long term by diminishing the duration and
severity of illness and the costs associated with ineffective treatment
and avoidable ADEs.

About RDx

RDx is a full-service, high-technology laboratory. We are fast,
accurate, and deliver value-based service nationally. RDx is accredited
by the College
of American Pathologists (CAP)
as a certified, full-service medical
laboratory. Visit http://www.rdxbioscience.com/

Contacts

Media:
CPR for RDx
Brittany Tedesco
btedesco@cpronline.com
201.641.1911 x14